港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

維立志博-B

61.350

+0.5500.90%

成交量：36.82萬

成交額：2,257.84萬

市值：122.09億

市盈率：-30.55

高：62.500

開：60.800

低：59.500

收：60.800

52周最高：83.600

52周最低：44.720

股本：1.99億

香港流通股本：1.53億

量比：1.03

換手率：0.24%

股息：- -

股息率：- -

每股收益(LYR):-2.008

淨資產收益率：--

總資產收益率：--

市淨率：102.85

市盈率(LYR):-30.55

市銷率: - -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

每日沽空追蹤 | 維立志博-B 02月11日沽空量成交1.6萬股，沽空比例為4.82%

維立志博-B盤中異動下午盤快速下跌5.03%

維立志博-B(09887)：維利信™於複發性或轉移性三陰性乳腺癌IB/II期試驗的首例患者用藥

瞄準 PD-1 未竟需求，雙抗/TCE/ADC 三箭齊發引領腫瘤免疫新升級｜專訪維立志博創始人康小強博士

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09887"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"維立志博-B","latestPrice":61.35,"timestamp":1770970089003,"preClose":60.8,"halted":0,"volume":368223,"delay":0,"changeRate":0.009046052631579017,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"已收盤","change":0.55,"latestTime":"02-13 16:08:09","open":60.8,"high":62.5,"low":59.5,"amount":22578365,"amplitude":0.049342,"askPrice":61.35,"askSize":200,"bidPrice":60.95,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-1.583,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1771205400000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":60.8,"openAndCloseTimeList":[[1770946200000,1770955200000],[1770958800000,1770969600000]],"volumeRatio":1.028141,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-2.008042,"volumeRatio":1.028141,"shares":199000000,"dividePrice":0,"high":62.5,"amplitude":0.049342,"preClose":60.8,"low":59.5,"week52Low":44.72,"pbRate":"102.85","week52High":83.6,"institutionHeld":0,"latestPrice":61.35,"committee":0.5,"eps":-2.008042,"divideRate":0,"volume":368223,"delay":0,"ttmEps":-1.583,"open":60.8,"prevYearClose":51,"prevWeekClose":62.7,"prevMonthClose":66.85,"prevQuarterClose":51,"fiveDayClose":62.7,"twentyDayClose":56.5,"sixtyDayClose":54.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1762185600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-02-12","current":-38.755527,"percent":0.586957,"low":-50.052922,"twenty":-42.341509,"median":-38.04671,"eighty":-33.367021,"high":-30.202688,"avg":-38.229865,"sd":4.579379,"marketCap":12092621440},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-12","current":-37.170656,"twenty":-42.341509,"median":-38.04671,"eighty":-33.367021,"marketCap":12092621440}],"updateTime":1770977219373},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610000912","title":"每日沽空追蹤 | 維立志博-B 02月11日沽空量成交1.6萬股，沽空比例為4.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610000912","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610000912?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 16:30","pubTimestamp":1770798645,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间02月11日，跌5.11%，卖空量成交1.6万股，较上一交易日减少24.53%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163617a4973342&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163617a4973342&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000500386.USD","HK0000252152.HKD","09887","HK0000252160.HKD","BK1161"],"gpt_icon":0},{"id":"2610900729","title":"維立志博-B盤中異動 下午盤快速下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610900729","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610900729?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 15:17","pubTimestamp":1770794242,"startTime":"0","endTime":"0","summary":"2026年02月11日下午盘15时17分，维立志博-B股票出现波动，股价快速跳水5.03%。截至发稿，该股报60.450港元/股，成交量29.03万股，换手率0.19%，振幅4.79%。维立志博-B股票所在的生物技术行业中，整体涨幅为0.60%。维立志博-B公司简介：我们是一家临床阶段生物科技公司,致力于创新疗法的发现、开发及商业化,以满足中国及全球在肿瘤、自身免疫性疾病及其他重大疾病方面未获满足的医疗需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021115172297a5beaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021115172297a5beaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000500386.USD","HK0000252160.HKD","BK1161","HK0000252152.HKD"],"gpt_icon":0},{"id":"2610861798","title":"維立志博-B(09887)：維利信™於複發性或轉移性三陰性乳腺癌IB/II期試驗的首例患者用藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2610861798","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610861798?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 16:38","pubTimestamp":1770712703,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，评价维利信用于治疗复发性或转移性三阴性乳腺癌的Ib/II期临床研究首例患者已成功用药。该试验旨在评价奥帕替苏米单抗单独给药或联合白蛋白结合型紫杉醇治疗复发性或转移性三阴性乳腺癌患者的疗效及安全性。维利信亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。癌症是全球致病和致死的主要原因之一。在我国，乳腺癌每年新发病例数持续上升，估算达36万，死亡病例数达7.5万。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000500386.USD","HK0000252152.HKD","09887","HK0000252160.HKD"],"gpt_icon":0},{"id":"2609076519","title":"瞄準 PD-1 未竟需求，雙抗/TCE/ADC 三箭齊發引領腫瘤免疫新升級｜專訪維立志博創始人康小強博士","url":"https://stock-news.laohu8.com/highlight/detail?id=2609076519","media":"峰客访谈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609076519?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 16:31","pubTimestamp":1770366668,"startTime":"0","endTime":"0","summary":"超过 30 年创新药研发经验，其中 17 年以上抗体新药研发经验，领导多个抗癌抗体新药研发。临床数据显示，PD-1 对约 80% 的患者无效或最终耐药。根据目前已有的数据，LBL-024 在非小细胞肺癌、小细胞肺癌和肺外神经内分泌癌三个适应症的二期或注册性临床试验中展示出全球首创和同类最优潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206170038a483eb3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206170038a483eb3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000500386.USD","HK0000252160.HKD","BK1161","09887","HK0000252152.HKD"],"gpt_icon":0}],"pageSize":4,"totalPage":40,"pageCount":1,"totalSize":160,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/09887\",params:#limit:6,delay:false,,,undefined,":[]}}